

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION OF THE GROUP'S PRODUCTS

The board of directors (the "Board") of The United Laboratories International Holdings Limited (the "Company") is pleased to announce that the bulk amoxicillin product as researched and developed by 聯邦制藥(內蒙古)有限公司 (United Laboratories (Inner Mongolia) Co., Ltd., a wholly-owned subsidiary of the Company) has recently approved by China State Food and Drug Administration with approval number "Guoyao Zunzi H20113028".

The bulk amoxicillin product is manufactured by the most advanced enzyme production process with high quality and purity, less pollution characteristics, and reduce the production costs. It is a revolutionary technology breakthrough in the Group's production technology. United Laboratories is currently the only one pharmacy manufacturer in China applying the enzymatic production process in bulk amoxicillin production.

By Order of the Board of
**The United Laboratories
International Holdings Limited**
Choy Kam Lok
Chairman

Hong Kong, 11 March 2011

As at the date of this announcement, the Board comprises Mr. Choy Kam Lok, Ms. Peng Wei, Mr. Leung Wing Hon, Mr. Tsoi Hoi Shan, Ms. Zou Xian Hong, Ms. Zhu Su Yan and Mr. Fang Yuping as executive directors; Ms. Choy Siu Chit as non-executive director; and Mr. Chong Peng Oon, Mr. Huang Bao Guang and Mr. Song Ming as independent non-executive directors.